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Abstract  
This study was conducted to detect three genetical variants of Extended-Spectrum Beta-
Lactamase (ESBL, in which142 Klebsiella pneumoniae (K.pneumoniae) isolates were collected 
from sections of a teaching hospital in Isfahan and were detected using standard IMVIC biochemical 
tests and urease. These were confirmed by identification of the ureD gene. Antimicrobial 
susceptibility testing was performed using the standard Kirby-Bauer disk-diffusion method on 
Mueller-Hinton agar (Merck,Germany) .The performance and interpretation were based on the 
guidelines from the Clinical Laboratory Standards Institute (CLSI, 2013). Screening and phenotypic 
identification of ESBLs isolates were performed by DDST. The presence of genes responsible for 
ESBL resistance, such as SHV, PER and VEB type ESBL genes was identified by PCR and 
indicator isolates sequencing performed by Macrogen (Seoul, Korea). The nucleotide sequences 
were analysed using the BLAST program (http://www.ncbi.nlm.nih.gov/BLAST), the Lahey 
database, and CromasPro-2 and Mega-4 software to determine the subvarients of the three variants 
of ESBL (SHV, PER, VEB). These were compared with blaSHV-11 gene from K. pneumonia 
(accession.no.X98101), blaSHV-5 gene from K. pneumonia (accession no. X55640), blaPER-1 gene 
from P.aeruginosa transposed on Tn2345 (accession no AY866517.2) and blaVEB-1 gene from K. 
pneumonia (accession no. AF010416). A total of 120 isolates (84%) were recognized as MDR. The 
highest rate of resistance was recorded for piperacillin (80%), ceftazidime (76%), and cefotaxime 
(73%) and the lowest rate was for ertapenem (47.3%), meropenem (50.8%), and imipenem (58.7%) 
following detection of ESBL isolates of K.pneumoniae (101 isolates; 71%).The ward and the 
clinical specimen with the most prevalence were ICU with 55(38.7%) and urine with 61(42.9%). 
The lowest prevalence was related to the neurosurgery ward with 8(5.6%) samples and the clinical 
specimen with the lowest prevalence was cerebrospinal fluid (CSF) with 2 (1.4%) samples. PCR 
detection in ESBL-producing K. pneumoniae showed that, of the clinical isolates, 42.2% contained 
blaSHV (42/101), 2.9% contained blaVEB (3/101) and2% contained blaPER (2/101). Sequencing of 
10 selected PCR products of SHV genes showed that 7/10isolates were similar to the strain SHV-11 
and 3/7 isolates were similar to the strain SHV-5. The sequencing of two PCR products of the PER 
genes showed they were similar to the strainPER-1.Sequencing of three PCR products of the VEB 
genes showed they were similar to the strain VEB-1. The overall prevalence of ESBL-producers was 
found to vary greatly in different geographical areas; this may be the result of differences in the type 
and amount of antibiotics consumed and differences in the time of collection of isolates. The present 
study reflects anincrease in the prevalence of ESBL-producers in Iran. The most common ESBL 
  
Hossein Fazeli, Razie Kamali Dolatabadi, Azade Taraghian, Bahram Nasr Isfahani, Sharareh Moghim 
 
 
 
Openly accessible at http://www.european-science.com                                                                   192 
 
type found in this study was SHVand that VEB and PER types were rare. In addition, sequence 
analysis results of our study show the rate of SHV-11, PER-1 and VEB-1was maximum. This study 
showed that ?-lactamase-producing K. pneumoniae strains are an emerging threat in ICUs. They 
should be monitored through the implementation of timely identification and strict isolation methods 
that will help to reduce adverse outcomes and mortality rates in patients. 
Keywords: blaSHV/VEB/PER genes , ESBL-producing MDR, Klebsiella pneumonia strains 
 
Introduction 
Microbial resistance through extended-spectrum beta-lactamase (ESBL) was first reported in 
the early1980s in Europe and then in the United States soon after the introduction of third-
generation cephalosporins to clinical practice (Hassan and Abdalhamid, 2014). The enzyme β-
lactamase continues to be the leading cause of resistance to betalactam antibiotics in gram-negative 
bacteria. There has been an increased incidence and prevalence of ESBL enzymes that hydrolyze 
and cause resistance to oxyimino-cephalosporins and aztreonam (Versalovic et al, 2011). More than 
300 different ESBL variants have been described (Ahmed et al, 2013). Although temoneira (TEM) 
and sulphydryl variable (SHV) variants are the most common ESBLs, strains expressing CTX-M 
ESBL have begun to emerge ( Ahmed et al, 2013). 
The dominant enzyme variants until the late 1990s were TEM,SHV and OXA( Livermore 
and Hawkey, 2004; Livermore et al, 2007). New families of  ESBLs have emerged (6), including 
families of pseudomonas extended-resistance (PER) and Vietnamese extended-spectrum beta–
lactamase (VEB) ( Stürenburg and Mack, 2003). VEB and PER variants are rare and are valuable 
for study. PER-1 was first detected in Pseudomonas aeruginosa (Nordmann et al, 1993) and later in 
Salmonella enteric and Acinetobacter isolates. PER-2, which shows 86% homology to PER-1, has 
been reported in S. enterica, E. coli, Klebsiella pneumoniae, Proteus mirabilis, and Vibrio cholera 
O1 El Tor (Bauernfeind et al, 1996; Petroni et al , 2002). 
The blaSHV genes are responsible for the production of SHV ?-lactamases , large families of 
enzymes with evolutionary affinity. Of the 172 enzyme types in the SHV family, 45are extended-
spectrum ?-lactamases on transferable elements such as plasmids and transposons (Al-Jasser, 2006; 
Shah et al, 2004) . This localization of bla genes can facilitate horizontal spreading of antibiotic 
resistance among bacterial strains (El Salabi and Walsh, 2013). 
K. pneumonia resides in the intestinal tract of about 40% of humans and animals. It is an 
opportunistic human pathogen, meaning that under certain conditions it can cause disease. For 
example, nosocomial infections are those contracted by hospitalized patients in a weakened state 
(Manikandan and Amsath, 2013). K. pneumoniae causes recurrent cough and acute exacerbation of 
chronic obstructive pulmonary disease defined as presence of increased sputum volume, purulence 
and dyspnea and is responsible for 30-50% of exacerbations (Madhavi, 2012). K. pneumoniaeis 
naturally resistant to ampicillin, but not to extended-spectrum β-lactam antibiotics. Many factors can 
contribute to the resistance of bacteria towards antibiotics. Adaptation of bacteria to stressful 
environments can result in bacteria adaptation, survival and growth. This could ultimately result in 
the production of ESBL producers in K. pneumonia (Puspanadan et al, 2013). 
 
Materials and Methods 
Sampling 
The samples tested comprised 500 clinical samples from urine, the trachea and bronchi, 
blood, sputum, ascetic fluid, CSF, abscesses and wounds were collected from sections of a teaching 
hospital in Isfahan (pediatrics, internal medicine, ICU, surgery, emergency, other). K.pneumoniae 
isolates were detected in 28% (142) of the samples using standard IMVIC biochemical tests (indole, 
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methyl red, Voges- Proskauer, citrate) and urease. These were confirmed by identification of the 
ureDgene (243bp), which is responsible for hydrolysis of urea (Mashouf et al, 2014).K. pneumoniae 
ATCC 700603 was used as the positive control. The target gene primers were lyophilized as listed 
below: 
ure –D F: 5_-CCCGTTTTACCCGGAAGAAG - 3 
ure –D R: 5_ - GGAAAGAAGATGGCATCCTGC -3 
Antimicrobial susceptibility testing 
Antimicrobial susceptibility testing was performed using the standard Kirby-Bauer disk-
diffusion method on Mueller-Hinton agar (Merck,Germany). Antibiotic discs (Mast, England) were 
used for early detection of K.pneumoniae isolates that produce ESBLs. The performance and 
interpretation were based on the guidelines from the Clinical Laboratory Standards Institute (CLSI, 
2013). The following antimicrobial agents were tested: ceftazidime, cefepim, azreonam, 
levofloxacin, ticarcillin, cefotaxim, amoxicillin/clavulanicacid, piperacillin/tazobactam, piperacillin, 
gentamicin, amikacin, and ciprofloxacin. E. coli ATCC 25922 was used as a control. 
Screening and phenotypic identification of ESBLs by DDST 
In initial detection, isolates showing resistance or decreased sensitivity to more than one of 
the third generation cephalosporins(3GC-ceftazidime, cefotaxime) were selected as probable ESBL 
producers (Anjali et al, 2013). The phenotype was confirmed by DDST where the tested strains were 
lawn cultures (0.5 McFarland std.) on Mueller-Hinton agar. Antibiotic disks of ceftazidime and 
ceftazidime-clavulanic acid were placed 15 mm apart and the plates were placed under aerobic 
incubation at 37°C. An increase of more than 5 mm in zone diameter for either antimicrobial agent 
tested in combination with clavulanic acid over the initial zone diameter of the agent when tested 
alone was considered proof of ESBL. E. coli ATCC 25922 was used as a negative control and K. 
pneumonia ATCC700603 as a positive control. 
Genotypic identification of ESBLs 
Preparation of DNA template 
The DNA template for K. pneumonia was prepared from freshly cultured isolates by 
suspending 3-5 colonies from the plate in 500 μl of transposon buffer and boiling it for 10 min. 
After boiling, the samples were cooled at -20°C for 5 min before centrifuging at 10,000 rpm for 10 
min (Amjad et al, 2011). 
Genotypic detection of bla genes by PCR 
The supernatant obtained was used as the DNA template in polymerase chain reaction(PCR) 
analysis. The strains were documented as ESBL by molecular detection of blaSHV, blaVEB, blaPER by 
PCR. The primers used for the detection of these genes are shown in Table 1. 
PCR was performed in 30 μl mixture of 3 μl 10X buffer, 1 μl of 10 mM MgCl2, and 0.25 μl 
of 5 U/μl Taq DNA polymerase (Fermentas, Lithuania), 0.5μleach of 10 mM deoxynucleaotide 
triphosphates, 1 μl each of 10 μM primers and 5 μl of plasmid extract in a thermal cycler (Kyratec, 
Korea). 
DNA sequencing analysis 
DNA sequencing for the 15 strains was performed to identify the bla genes. The PCR 
products of the genes were further purified using PCR purification kits (Fermentas) and subjected to 
direct sequencing performed by Macrogen (Seoul, Korea) as described previously (Shacheraghi et 
al, 2010). The nucleotide sequences were analysed using the BLAST program 
(http://www.ncbi.nlm.nih.gov/BLAST), the Lahey database, CromasPro-2 and Mega-4 softwareto 
determine the subvarients of the three variants of ESBL (SHV, PER, VEB). These were compared 
with blaSHV-11 gene from K. pneumonia (accession.no.X98101), blaSHV-5 gene from K. pneumonia 
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(accession no. X55640), blaPER-1 gene from P.aeruginosa transposed on Tn2345 (accession 
no.AY866517.2) and blaVEB-1 gene from K. pneumonia (accession no. AF010416). 
 
Table1: Primers used for amplification of ESBLs genes 
 
Statistical analysis 
Statistical analysis was performed using Whonet(v. 5.6) software on the data according to 
CLSI2013. 
 
Results 
The 142 clinical isolates of K.pneumoniae were identified by biochemical methods and confirmed 
by PCR for the ureD gene. All isolates were positive for ureD gene, which confirmed their identity 
as K. pneumonia.  
 
 
Figure 1. Agarose gel showing ureD gene. Lane 1: Ladder, Lane2: positive control 
(K.pneumoniae ATCC700603), Lane3-5: test isolates.Lane6: Negative control (Escherichia coli 
ATCC 25922 
Primer Nucleotide   sequences Expected Size PCR conditions 
 
SHV-F 
SHV-R 
 
ATGCGTTATATTCGCC
TGTG 
TGCTTTGTTATTCGGG
CCAA 
 
753 
95°C, 5 min; 34 cycles of 
94°C, 30 sec, 54°C, 30 sec, 
72°C, 45 sec,72°C, 10min 
 
 
 
VEB-F 
VEB-R 
 
 
CGACTTCCATTTCCCG
ATGC 
GGACTCTGCAACAAAT
ACGC 
 
 
643 
95°C, 5 min; 34 cycles of 
94°C, 30 sec, 58°C, 30 sec, 
72°C, 45 sec,72°C, 10min 
 
 
 
PER-F 
PER-R 
 
AAAGAGCAAATTGAAT
CCATAGTC 
GTTAATTTGGGCTTAG
GGCAG 
 
835 
95°C, 5 min; 34 cycles of 
94°C, 30 sec, 56°C, 30 sec, 
72°C, 45 sec,72°C, 10min 
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Of the 142 clinical isolates of K. pneumonia, 57% were from males and 43% were females. 
In this study multi-drug resistant (MDR) K. pneumonia was defined as an isolate resistant to at least 
three classes of antimicrobial agents (Ben et al, 2006). A total of 120 isolates (84%) were 
recognized as MDR. The breakdown of the resistance rates between antibiotics is given in Figure 1 
and 2. 
 
 
Figure 2: Pattern of Resistance to Antimicrobial agents among all K. pneumonia. Strains 
a Abbreviations: CAZ, ceftazidime; CTX:Cefotaxime; ATM:aztreonam; AMC, amoxicillin 
clavulanic acid; IPM, Imipenem; MEM, Meropenem; ETP, Ertapenem;GEN; gentamicin; 
CIP, ciprofloxacin; FEP, cefepime;AMK, amikacin; PIP, piperacillin; TZP, 
Piperacillin/tazobactam; LVX, Levofloxacin;TET, tetracycline; R, Resistance; S, Sensitive; 
I,Intermediate. 
  
 
Figure 3: Result of DDST of K. pneumoniae strain CE: cefotaxime (30 g), 
CEC, cefotaxime  +clavulanic acid (30/10 g)  
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The highest rate of resistance was recorded for piperacillin (80%), ceftazidime (76%), and 
cefotaxime (73%) and the lowest rate was for ertapenem (47.3%), meropenem (50.8%), and 
imipenem (58.7%) following detection of ESβL isolates of K.pneumoniae(101 isolates; 71%).Figure 
3 shows the results of DDST of a K.pneumoniae strain isolated from an eviscerated material along 
with the positive and negative control strains. 
 The prevalence of the enzyme in different clinical specimens (urine, the trachea and bronchi, 
blood, sputum, ascetic fluid, CSF, abscess, and wound) in different sections of the hospital 
(pediatrics, internal medicine, ICU, surgery, emergency, other) are showed in Tables 2 and 3. 
 
Table 2. Prevalence of K.pneumoniae ESBL among different clinical specimens 
 
The highest proportion of K.pneumonia was isolated from urine samples (61; 42.9%) and in 
the ICU (55; 38.7%). The lowest proportion was from CSF (2; 1.4%) and neurosurgery (8; 5.6%).  
PCR detection in ESBL-producing K. pneumoniae showed that, of the clinical isolates, 
42.2% contained blaSHV(42/101), 2.9% contained blaVEB(3/101) and2% contained blaPER (2/101) 
cases contained blaSHV, blaVEB and blaPER (Figures 3, 4 and 5). 
 
Table 3. Prevalence of K.pneumoniae ESBL among different sections of the hospital 
Specimen type Number of patients (%) ESBL 
+(%) - (%) 
ascetic fluid 5(3.5%) 5 0 
Abscess 3(2.1%) 1 2 
Blood 3(2.1%) 2 1 
Bronchi 14(9.8%) 14 0 
Catheter 7(4.9%) 7 0 
Cerebrospinal fluid 2(1.4%) 2 0 
Sputum 4(2.8%) 3 1 
Trachea 28(19.8%) 23 5 
Urine 61(42.9%) 36 25 
Wound 14(9.8%) 8 6 
Total 142(100%) 101(71%) 31(29%) 
Location Number of isolates(%) ESBL 
+ - 
Pediatrics 9(6.3%) 4 5 
internal medicine 27(19%) 20 7 
ICU 55(38.7%) 45 10 
Surgery 27(19%) 16 11 
Emergency 16(11.2) 9 7 
Neurosurgery 8(5.6) 7 1 
Total 142(100%) 101(71%) 31(29%) 
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Figure 3: Gel electrophoresis of blaSHV gene 
 
 
Figure 4: Gel electrophoresis of blaVEB gene 
 
 
Figure 5: Gel electrophoresis of blaPER gene 
 
SHV-type ESBL was the most common and PER-type ESBL was least common. The 
distribution of the blaSHV, blaVEB and blaPER is shown in Table 4. 
 
Table 4: distribution of ESBL genes among different samples 
Specimen type ESBL (%) SHV VEB PER 
Abdominal fluid 3.5% 4 0 0 
Abscess 0.7% 3 0 1 
Blood 1.4% 4 0 0 
Bronchial 9.8% 6 1 0 
Catheter 4.9% 0 0 0 
Cerebrospinal fluid 1.4% 1 0 0 
Sputum 2.1% 4 0 0 
Tracheal 16.1% 7 1 1 
Urine 25.3% 7 1 0 
Wound 5.6% 6 0 0 
Total 71% 42 3 2 
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Sequencing of 10 selected PCR products of SHV genes showed that 7/10 isolates were 
similar to the strain SHV-11 (blaSHV-11gene from K. pneumonia; accession.no.X98101) and 3/7 
isolates were similar to the strain SHV-5 (blaSHV-136gene from K. pneumonia accession no. 
X55640). 
The sequencing of two PCR products of the PER genes showed they were similar to the 
strainPER-1 (blaPER-1 gene from P.aeruginosa transposon Tn2345; accession 
no.AY866517.2).Sequencing of three PCR products of the VEB genes showed they were similar to 
the strain VEB-1 (blaVEB-1 gene from K. pneumonia; accession no. AF010416). 
 
Discussion  
Identification of common etiologic organisms of nosocomial pathogens and their patterns of 
antibiotic resistance is of great importance for controlling disease and reducing medical costs. Since 
members of Enterobacteriaceae are the main contributors to nosocomial and community-acquired 
infections, establishing a new strategy for diagnosis and treatment of ESBL-producing bacteria is 
essential. The prevalence of ESBL-producing bacteria differs greatly worldwide and mainly depends 
on the extent of use of beta-lactam antibiotics in a community (Moghaddam et al, 2014). 
Infection with MDR strains increase the duration of hospitalization and medical and surgical 
cost for a patient. In this study, about84%(120/142) of all isolates were MDR. This finding is in 
accordance with studies conducted in Iran, Pakistan, Mexico and India that reported the incidence of 
MDR K.pneumoniae (Al-Zarouni et al, 2008). 
The prevalence of ESBL-producing K. pneumoniae was 71%(101/142), which is higher than 
in India(66.7%) (Hoda Hassan, 2014) and Turkey(54.7%-61%) (Al-Zarouni et al, 2014). It is similar 
to other studies in Iran(72.1%) (Feizabadi et al, 2010) and much higher than reports from Saudi 
Arabia (25.2%), United Arab Emirates(41%) (Al-Zarouni et al, 2008) and Kuwait (31.7%) 
(Mokaddas et al, 2008).The overall prevalence of ESBL-producers was found to vary greatly in 
different geographical areas; this may be the result of differences in the type and amount of 
antibiotics consumed and differences in the time of collection of isolates. The present study reflects 
anincrease in the prevalence of ESBL-producers in Iran. In Iran, the majority of ESBL-producing 
isolates were recovered from urine, which is similar to results of other studies (Fam et al, 2011). 
The most common ESBL type found in this study was SHV, which is similar to that reported 
by Harada et al (2013). In Japan and different from the results reported by Jikun Du et al (2014). In 
China sequence analysis results show that the prevalenceof SHV-11 was similar to results by 
Feizabadi et al in Tehran (2010) and that VEB and PER types were rare.  
The results showed that two of the isolated K. pneumonia carried the blaPER gene. This 
statistic was about 55% in Turkey (Paterson et al, 2003) and was nil in other studies, which is 
similar to what has been reported for E. coli isolates by Shahcheraghi et al. (2010) in Tehran, 
Celenza et al. (2006) in Italy and Barguigua et al. (2011) in Morocco. The much higher prevalence 
(49.25%) of blaPER gene has been reported among ESBL-producing strains of P.aeroginosa isolated 
from burn patients. The blaPER-1 gene has been detected mainly in glucose-non-fermenting gram-
negative bacilli such as P.aeruginosa and Alcaligenesfaecalis; however, it has been recently found 
in Enterobacteriaceae and Aeromonas media (Picão et al, 2008; Lee et al, 2011; Umadevi et al, 
2011). This gene has recently been reported for the first time in K. pneumoniae. The authors are of 
the opinion that there is a possibility of further dissemination of the blaPER-1 gene in 
Enterobacteriaceae. 
 Some ESBL isolates have none of these three genes (blaSHV, blaVEB,blaPER). This may 
result from the presence of other genes responsible for ESBL resistance, such as blaTEM, blaCTX-M 
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and blaOXA). None of the isolatesin this study showed the presence of two or three ESBL-producing 
genes together. 
The prevalence of ?-lactamase-producing isolates and their isolation in life-threatening 
infections has increased dramatically worldwide. Intense pressure by patients to use PER-1 
antimicrobial drugs has resulted in the eradication of normal flora and substitution with MDR 
isolates.  
Phenotypic methods are the only screening methods available for the detection of ESBLs in 
a routine laboratory. Genotypic methods help confirm the genes responsible for ESBL production. 
This study showed that ?-lactamase-producing K. pneumoniae strains are an emerging threat in 
ICUs. They should be monitored throughthe implementation of timely identification and strict 
isolation methods that will help to reduce adverse outcomes and mortality rates inpatients. 
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